Custom CRISPR Multiplex sgRNA Vectors
Interested in knocking out multiple genes or recruiting transcriptional regulators using a combination of sgRNAs? abm’s CRISPR multiplex gRNA system allows for optimal expression of multiple gRNAs from alternating U6 and H1 RNA pol III promoters on a single lentiviral vector. gRNAs may be designed for use with any Cas9 variant, which is expressed from a separate vector (click here to see abm’s full list of Cas9-expressing vectors and viruses). Just tell us what you want to accomplish, and we’ll do the sgRNA design, cloning, and lentiviral packaging for you.
Additional Resources:
Service Details
sgRNA Service (for spCas9) | No. of sgRNAs | Quantity | Cat. No. | Price |
---|---|---|---|---|
Custom CRISPR Dual sgRNA Lentivector (for spCas9) | 2 | 1.0 ug | C420 | $395.00 |
Custom CRISPR Triple sgRNA Lentivector (for spCas9) | 3 | 1.0 ug | C421 | $595.00 |
Custom CRISPR Quad sgRNA Lentivector (for spCas9) | 4 | 1.0 ug | C422 | $795.00 |
Custom CRISPR Multiplex sgRNA Lentivector (for spCas9) | >4 | 1.0 ug | C423 | Inquire |
sgRNA Service (for saCas9) | No. of sgRNAs | Quantity | CAT. NO. | PRICE |
---|---|---|---|---|
Custom CRISPR Dual sgRNA Lentivector (for saCas9) | 2 | 1.0 ug | C511 | $395.00 |
Custom CRISPR Triple sgRNA Lentivector (for saCas9) | 3 | 1.0 ug | C512 | $595.00 |
Custom CRISPR Quad sgRNA Lentivector (for saCas9) | 4 | 1.0 ug | C513 | $795.00 |
Custom CRISPR Multiplex sgRNA Lentivector (for saCas9) | >4 | 1.0 ug | C514 | Inquire |
Packaging Options | Volume | CAT. NO. | PRICE |
---|---|---|---|
Custom Recombinant Lentivirus (106 IU/ml) | 10 ml | LV002 | $650.00 |
High Titer Custom Recombinant Lentivirus (107 IU/ml) | 1.0 ml | LV002-a | $850.00 |
High Titer Custom Recombinant Lentivirus (108 IU/ml) | 550 ul | LV002-b | $1100.00 |
High Titer Custom Recombinant Lentivirus (109 IU/ml) | 100 ul | LV002-c | $1350.00 |
High Titer Custom Recombinant Lentivirus (1010 IU/ml) | 100 ul | LV002-d | $1850.00 |
Additional Info
Applications
-
Multi-target genomic mutagenesis:
- Target multiple sites at a single locus or target multiple different loci simultaneously
- Convenient for use with Cas9 nickase to increase specificity and reduce off-target effects. Easily co-express multiple gRNAs simultaneously.
- sgRNAs can be designed for use with any Cas9 (saCas9, spCas9, dCas9-SAM, dCas9-KRAB, etc.)
-
Simultaneous activation, repression, knockout of multiple genomic targets:
- Activation using dCas9-SAM
- Repression using dCas9-KRAB
- Knockout using spCas9 or saCas9
Related Products
FAQs
What promoter(s) do your sgRNA and All-in-One lentivectors have? |
sgRNAs are expressed from the U6 promoter and All-in-One lentivectors and lentiviruses express Cas9 from the SFFV promoter.
|
What is the approximate time frame to generate CRISPR lentiviral constructs? |
The typical lead time is around 1-3 weeks for CRISPR lentivectors and 4-6 weeks for lentiviruses. Please inquire for a more accurate lead time.
|
How should I store my lentivirus? |
Aliquots should be made for the lentivirus and stored at -70 degrees Celsius.
|
If a high-titer custom lentivirus was ordered, do you do the lentiviral titration after a freeze-thaw or straight after production before the freeze-down step? |
We do the titration after aliquoting and freeze-down. Thus, the titer should be accurate for the customer after they thaw the finished product for the first time.
|
Which virus has your lentivirus expression system been derived from? Is it HIV? |
Our lentivirus expression system is derived from Human HIV-1 Virus. It employs third generation self-inactivating recombinant lentiviral vectors with enhanced biosafety features and minimal relation to wild-type Human HIV-1 Virus.
|
How do you verify the titer? |
We use our LV900 series - qPCR Lentivirus Titration(Titer) Kit. This kit quantifies a proprietary region of the lentiviral 5’-LTR.
|
What is the packaging capacity for Lentivirus? |
The maximum insert size is <9 kb between the 5'LTR to 3'LTR.
|
Citations
01 | Kang, Y. J. et al. "Regulation of NKT cell-mediated immune responses to tumours and liver inflammation by mitochondrial PGAM5-Drp1 signalling." Nat. Commun. (2015) 6:8371 doi: 10.1038/ncomms9371 |
02 | Jiang, G. et al. "Isorhapontigenin (ISO) inhibits invasive bladder cancer (BC) formation in vivo and human BC invasion in vitro by targeting STAT1/FOXO1 Axis." Cancer Prev Res. Published Online First April 14, 2016.doi: 10.1158/1940-6207.CAPR-15-0338 |
03 | Okugawa, Y. et al. "Clinical significance of SNORA42 as an oncogene and a prognostic biomarker in colorectal cancer." Gut (2015)doi:10.1136/gutjnl-2015-309359 |